

## Office of Medicinal Cannabis



## Release certificate

Product:

Cannabis flos, variety Bedrocan (hemp flowers)

Country:

to be sold on the pharmaceutical market

Strength:

tetrahydrocannabinol: approx. 22%

cannabidiol: <1.0%

Dosage form:

Flowers

Package size:

5 grams in container, 400 grams in bags

Batch:

18K12EY19B20

Order numbers:

contaniers: 357604 to 357614

bags:

not available

Grower/drier:

Bedrocan BV

P.O. Box 2009

harvest date/period: 12 November 2018

NL-9640 CA Veendam

Gamma irradiation:

Synergy Health Soevereinstraat 2

date: 20 Feb. 2019

≥ 10,0 kGy

dose:

NL-4879 NN Etten-Leur

Packager:

Fagron BV Venkelbaan 101 date:

2 - 9 April 2019

Part of analysis:

1.general analysis

2.microbiology of end product in

container

Laboratories:

**PROXY Laboratories BV** Archimedesweg 25

NL-2908 KE Capelle a/d IJssel

Bactimm BV

NL-2333 CM Leiden

Middenkampweg 17 NL-6545 CH Nijmegen

Analysis number:

1. 394-0112322

2. 04.413

Report date:

1. 20 December 2018

2. 16 April 2019 Analytical monograph by BMC / Farmalyse, version 7.1, Nov. 28, 2014

Testing method: End check:

Office of Medicinal Cannabis

date: 12 April 2019

	Method	Specification	Result
Appearance	monograph	brown green clustered flowers of 1,5 to 3 cm with a characteristic smell	conform
Identity			
microscopy	monograph	mainly gland hairs visible	conform
thin layer chromatography	monograph	monograph	conform
Foreign material	monograph	stalks, insects and other vermin are absent	conform
Fineness	monograph	<ul> <li>no leaves shooting out more than 20% of the length of the flowers</li> <li>stalks are cut away directly under the bottom flowers of the inflorescence</li> </ul>	conform


Telefax +31 70 340 7426

## Ministry of Health, Welfare and Sport

## Office of Medicinal Cannabis

Page 2 Our reference

18K12EY19B20



I hereby certify that the above information is authentic and accurate. This batch of product has been cultivated and manufactured, including packaging and quality control at the above mentioned sites in full compliance with the GAP requirements as published in the Dutch State Gazette (Staatscourant) as the annex to the Regulation of the Minister of Health, Welfare and Sport of 9 January 2003, GMT/BMC 2340685, and with the specifications as stated in this document. The batch processing, packaging and analysis records were reviewed and found to be in compliance with GAP and GMP.

The Hague, the Netherlands, 16 April 201

Dr. M. van de Velde

head Medicine Cannelis Velde